Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.
Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.
The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.
Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.
In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.
Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.
For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.
Teleflex Incorporated (NYSE: TFX) has announced the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) as a strategic branch of its Vascular Access business unit. Located in Research Triangle, North Carolina, TCAP is dedicated to reducing the spread of infections caused by multidrug-resistant organisms. The center aims to be a resource for patients, physicians, and healthcare organizations through education and partnerships with infection prevention professionals.
TCAP recently sponsored an educational webinar on healthcare-acquired infections, specifically central line-associated bloodstream infections (CLABSI). Teleflex's Arrow™ Brand of Vascular Access Products offers a comprehensive portfolio of antimicrobial Chlorhexidine catheters designed to provide broad-spectrum protection against various pathogens. The company also provides Arrow™ Maximal Barrier Kitting options to protect patients and improve procedural efficiency for clinicians.
Teleflex Incorporated (NYSE:TFX) has announced its upcoming second quarter 2024 earnings conference call, scheduled for Thursday, August 1, 2024, at 8:00 a.m. Eastern Time. The call will provide an opportunity for the company to discuss its financial results and offer an operational update. Interested parties can pre-register to receive dial-in information or access the call via a live audio webcast on the Teleflex website. An audio replay will be available from 11:00 am Eastern Time on the same day, accessible through the website or by phone using specific dial-in numbers and a conference ID.
Teleflex Incorporated (TFX) has released its 2023 Global Impact Report, showcasing achievements and outlining goals for its Corporate Social Responsibility (CSR) program. The report aligns with leading sustainability standards and emphasizes the company's commitment to social, environmental, and ethical initiatives. Key highlights include validation of net-zero greenhouse gas emissions by 2050, improved ESG ratings, renewable energy generation at manufacturing sites, and substantial research grants. The report reflects Teleflex's dedication to sustainability, stakeholder engagement, and environmental stewardship.
Teleflex Incorporated (TFX) has expanded its intraosseous vascular access portfolio with the launch of the Arrow™ EZ-IO™ Intraosseous Access Procedure Tray, the first FDA-cleared sterile, single-use IO tray in the market. This new tray includes a battery-powered driver and essential components for the IO access procedure, improving clinician workflow and patient care. The tray addresses the need for fast and precise vascular access, especially in time-critical situations where intravenous access is challenging. The development of this tray showcases Teleflex's commitment to innovation and empowering healthcare professionals.
Teleflex Incorporated presented new research findings at the American Urological Association Annual Meeting showcasing superior patient experience with the UroLift™ System for BPH. The studies demonstrated better symptom relief, quality of life improvements, and patient satisfaction compared to medication and other therapies. The UroLift™ System was found to provide rapid relief and durable outcomes with preservation of sexual function.
Teleflex Incorporated (TFX) declared a quarterly cash dividend of $0.34 per share for its common stock, payable on June 14, 2024, to shareholders of record on May 15, 2024.
Teleflex Incorporated reported first quarter financial results with revenues of $737.8 million, up 3.8% YoY, and GAAP diluted EPS of $0.33. The company lowered its GAAP revenue growth guidance to 3.35%-4.35% but raised its adjusted EPS guidance. Net revenue by segment showed growth in EMEA and OEM, while net revenue by global product category saw growth in Interventional and OEM. Other financial highlights included increases in cash, accounts receivable, and inventories. The company's outlook for 2024 includes lower revenue growth on a GAAP basis but higher diluted EPS. Non-GAAP financial measures were used to assess performance, with adjustments made for restructuring, acquisition, and integration expenses.
Teleflex Incorporated (NYSE: TFX) announced multiple clinical studies at the 2024 American Urological Association Annual Meeting, showcasing the UroLift™ System to treat benign prostatic hyperplasia. The studies include head-to-head RCT data presentations, post-surgery medication use analysis, and real-world evidence studies.
Teleflex Incorporated has announced the market release of the Wattson™ Temporary Pacing Guidewire, expanding its structural heart portfolio. The device offers dual functionality, supporting valve delivery and ventricular pacing during procedures like TAVR and BAV. Designed to reduce complications, costs, and procedural steps associated with traditional pacing methods, the guidewire aims to enhance procedural efficiency and safety.
Teleflex Incorporated (NYSE: TFX) Chairman, President, and CEO Liam Kelly will present at the BofA Securities 2024 Health Care Conference on May 14, 2024, in Las Vegas. The live audio webcast will be accessible on the Teleflex website.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
What does Teleflex Incorporated do?
Where is Teleflex Incorporated headquartered?
How many people does Teleflex employ?
What are the main segments of Teleflex's business?
What percentage of Teleflex’s revenue comes from the United States?
What recent acquisitions has Teleflex made?
What is the UroLift™ System?
What was Teleflex's revenue growth in 2023?
How can one access Teleflex's investor conference calls?
What is the mission of Teleflex Incorporated?
